The Dynamics of Pharmaceutical Patenting in India: Evidence from USPTO Data

Simonetti, Roberto; Archambault, Éric; Côté, Grégoire; Kale, Dinar

doi:10.1080/09537320701521382

Cited by 17 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings may thus be interpreted to reflect a process experienced by a certain group of firms. For instance, some Indian pharmaceutical firms choose to catch up via imitation (Simonetti et al 2007). However, what matters may not be the characteristics of an industry or of a country but the strategy that a firm chooses.…”

Section: Limitationsmentioning

confidence: 99%

“…Conversely, in India, pharmaceutical firms typically begin with duplicative imitation, which is followed by creative imitation as these firms rise up the value chain of pharmaceutical research and development (R&D). The patenting rates of Indian pharmaceutical firms have increased dramatically in recent years (Simonetti et al 2007), and regulatory changes have played an important role in facilitating the creation of dynamic capabilities in these firms (Athreye, Kale, and Ramani 2009). However, in the Republic of Korea, where large diversified conglomerates are common, firms' R&D and learning strategies are more independent than such strategies in India (Choung, Hameed, and Ji 2012;Lee 2005;Lee and Yoon 2010).…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Open innovation and intellectual property strategy: the catch-up processes of two Chinese pharmaceutical firms

Ren

2015

Technology Analysis & Strategic Management

View full text Add to dashboard Cite

We explore the interaction of open innovation and intellectual property (IP) in two Chinese latecomer pharmaceutical firms in their catch-up process. Studying archival data, documentation, and interviews, we found that the two firms exhibited five periods that were characterised by different open innovation activities and R&D capabilities. In their early stages, the two firms lacked R&D functions; thus, they imported technologies and pursued productionoriented strategies. As they gradually entered into collaborations and established their R&D departments, open innovation and IP protection played important and dynamic roles in this process. Thus, a catch-up process involves not only acquiring technological capabilities and innovative competencies but also transforming a firm's capacity to strategies.

show abstract

Section: Limitationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Open innovation and intellectual property strategy: the catch-up processes of two Chinese pharmaceutical firms

Ren

2015

Technology Analysis & Strategic Management

View full text Add to dashboard Cite

show abstract

“…This enabled firms to reproduce and sell products produced by international firms by using alternate processes to manufacture them. Tired of seeing pharmaceutical markets “lost to successful imitators” (Lanjouw and Cockburn, 2001, p. 268), governments such as the US placed intense pressure on India to comply with World Trade Organization regulations and pass the new patent law (Simonetti et al , 2007).…”

Section: India Biotechnology Industrymentioning

confidence: 99%

High technology in emerging markets

Ahn

Hajela

Akbar

2012

Asia-Pacific Journal of Business Administration

View full text Add to dashboard Cite

PurposeBuilding a bioeconomy requires efficient technology transfer and global linkages to exploit finite intellectual property exclusivity periods. Using a resource‐based view lens, this paper aims to assess the priorities, capabilities, and competitiveness of the emerging bioeconomy in India.Design/methodology/approachA triangulated design was used that involved interviews, case studies and a survey of 61 India biotechnology industry participants.FindingsTwo high priority capabilities were identified as being critical to fostering a competitive bioeconomy – access to talent and access to funding. Participants also identified the critical role of government in building and coordinating infrastructure, enabling critical capabilities, and accelerating bi‐directional technology and capital flows. This study reinforces the resource‐based view strategy framework regarding the importance of local context for biotechnology research.Practical implicationsImplications include the need for public‐private sector collaboration to strengthen industry infrastructure and enable biotechnology start‐ups, partnering between academia and government to accelerate technology transfer, and importance of seeking international investment and alliances early in a company's lifecycle to ensure sustainability.Originality/valueThese India‐centric lessons may be valuable in advancing knowledge for building successful biotechnology clusters, particularly for emerging market countries.

show abstract

Innovation strategy of latecomer firms under tight appropriability regimes: The Indian pharmaceuticals industry

Ray

2021

Journal of International Management

View full text Add to dashboard Cite

The Dynamics of Pharmaceutical Patenting in India: Evidence from USPTO Data

Cited by 17 publications

References 5 publications

Open innovation and intellectual property strategy: the catch-up processes of two Chinese pharmaceutical firms

Open innovation and intellectual property strategy: the catch-up processes of two Chinese pharmaceutical firms

High technology in emerging markets

Innovation strategy of latecomer firms under tight appropriability regimes: The Indian pharmaceuticals industry

Contact Info

Product

Resources

About